[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354217-105":59,"doc-detail-354217-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","salivary-metabolic-characteristics-and-response-to-neoadjuvant-systemic-therapy-in-breast-cancer","Salivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer","","Metabolic changes in saliva correlate with non-oral cancers, with breast cancer particularly linked to salivary biomarker behavior. The study evaluates whether clinical, pathological, molecular, and salivary characteristics can assess response to neoadjuvant chemotherapy in 361 breast cancer patients and 127 healthy controls. Saliva metabolites covering amino acids, lipids, and tumor markers were compared with post-surgery pathomorphism. Response differences emerged with menopause status, HER2-negative disease, differentiation, and hormone receptor expression. BMI>25, HER2-low, and multidirectional metabolite shifts defined informative signatures. Favorable prognostic patterns included reduced urea, altered absorption at 2957 cm−1, and increased CA27.29 and CA-15-3.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/salivary-metabolic-characteristics-and-response-to-neoadjuvant-systemic-therapy-in-breast-cancer/354217/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/salivary-metabolic-characteristics-and-response-to-neoadjuvant-systemic-therapy-in-breast-cancer/354217.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main aim of this study?","Question",{"text":113,"@type":114},"To comprehensively analyze clinical, pathological, molecular, and salivary characteristics for assessing response to neoadjuvant chemotherapy in breast cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was saliva used to evaluate therapy response?",{"text":118,"@type":114},"Saliva samples were collected before treatment, and analyses of amino acids, lipids, and tumor markers were compared with pathological assessment after surgery.",{"name":120,"@type":111,"acceptedAnswer":121},"Which salivary factors were identified as prognostic indicators?",{"text":122,"@type":114},"The study highlighted multidirectional metabolite changes, including reduced urea and altered absorption at 2957 cm−1, along with increased CA27.29 and CA-15-3, and identified CA15-3 concentration in saliva as an independent prognostic indicator.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354217,1790143628,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nSalivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer  \nLyudmila V. Bel’skaya   \nAcademic Editor: Sabrina Lisi  \nReceived: 21 April 2026  \nRevised: 6 May 2026  \nAccepted: 14 May 2026  \nPublished: 16 May 2026  \nCopyright: © 2026 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nBiochemistry Research Laboratory, Omsk State Pedagogical University, 644099 Omsk, Russia; [belskaya@omgpu.ru](belskaya@omgpu.ru)  \nAbstract  \nMetabolic changes in saliva are known tobe closely associated with the presence of non-oral cancers, particularly breast cancer. The diagnostic and prognostic potential of salivary biomarkers in breast cancer has been demonstrated, but their applicability for assessing therapy response has not yet been established. The aim of this study was to comprehensively analyze clinical, pathological, molecular, and salivary characteristics when assessing the response to neoadjuvant chemotherapy for breast cancer. The study included 361 breast cancer patients undergoing their first course of chemotherapy and 127 healthy volunteers without breast pathologies. Saliva samples were collected from all volunteers before treatment. Saliva analysis results for amino acids, lipids, and tumor markers were compared with tumor pathomorphism assessment after breast cancer surgery. The proportion of patients with a complete response to therapy was statistically significantly lower after menopause, and in those with HER2-negative breast cancer, moderate tumor differentiation, and high estrogen and progesterone receptor expression. For the first time, a body mass index (BMI) greater than 25 and low HER2 expression (HER2-low) were shown to have an unfavorable prognosis. The criterion for selecting informative salivary metabolites was a multidirectional change in minimal and complete pathological responses to therapy compared to healthy controls. Thus, prognostically favorable signs were a decrease in the concentration of urea below 7.5 mmol/L (OR = 1.921; 95% CI 1.061–4.270; p = 0.0342), a decrease in the area of the absorption band at 2957 cm−1 below 24 (OR = 3.875; 95% CI 1.160–12.70; p = 0.0003), and an increase in the concentration of cancer antigen CA27.29 above 3 U/L (OR = 2.138; 95% CI 1.021–7.273; p = 0.0343) and CA-15-3 above 39 U/L (OR = 3.896; 95% CI 1.062–14.07; p = 0.0072) . With a simultaneous increase in both CA27.29 and CA15-3, the probability of a complete response to therapy increased (OR = 4.288; 95% CI 1.056–17.09; p = 0.0013) . Multivariate analysis showed that an independent prognostic indicator, along with the expression status of HER2, estrogen receptors, differentiation degree, BMI, and menopause status, was the concentration of CA15-3 in saliva (AUC = 0.789, 95% CI: 0.737–0.842, p = 0.0001) . Identifying new markers will help physicians formulate treatment plans tailored to a patient’s individual risk factors, leading to increased survival and improved quality of life.  \nKeywords: breast cancer; neoadjuvant chemotherapy; pathological response; pathomorphism; saliva; treatment response; prognostic biomarkers  \n1. Introduction  \nA global trend in the treatment of aggressive stage II–III breast cancer is neoadjuvant chemotherapy (NACT) [1,2]. This initial drug-based approach improves immediate patient  \noutcomes, including reducing locoregional treatment time. Additional stratification of patients into a favorable prognosis group (those who have achieved complete tumor regression at the neoadjuvant stage) and a high-risk group (those with residual tumor) allows for improved survival through escalation of subsequent adjuvant therapy [3,4] . It is also necessary to evaluate the pathological response of the tumor to NACT, which is a strategically important factor for developing a further treatment algorithm and assessing the prognosis f","cbCaitmmwRDBq67K","https://ap.wps.com/l/cbCaitmmwRDBq67K","pdf",1002924,22,"English","# Introduction\n## Neoadjuvant chemotherapy in stage II–III breast cancer\n## Need for pathological response assessment\n## Current prognostic biomarker research\n## Established multigene assays and molecular predictors\n## Emerging approaches: saliva and metabolomics","[{\"question\":\"What was the main aim of this study?\",\"answer\":\"To comprehensively analyze clinical, pathological, molecular, and salivary characteristics for assessing response to neoadjuvant chemotherapy in breast cancer.\"},{\"question\":\"How was saliva used to evaluate therapy response?\",\"answer\":\"Saliva samples were collected before treatment, and analyses of amino acids, lipids, and tumor markers were compared with pathological assessment after surgery.\"},{\"question\":\"Which salivary factors were identified as prognostic indicators?\",\"answer\":\"The study highlighted multidirectional metabolite changes, including reduced urea and altered absorption at 2957 cm−1, along with increased CA27.29 and CA-15-3, and identified CA15-3 concentration in saliva as an independent prognostic indicator.\"}]","Salivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer | PDF",1790109568,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/488309a78190e0466d976efec3f6c49d.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf5524078a260441207f2a778cbe043d.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b05330df5d2fda4f1df9c9e2f4c711e.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a3176cd4636cdfece1a5021a9f93915.webp",980,1385]